Get the Stockscreener App
61.06
1.08%
-0.665
After Hours:
61.07
0.005
+0.01%
Monopar Therapeutics Inc stock is traded at $61.06, with a volume of 401.63K.
It is down -1.08% in the last 24 hours and down -24.03% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$61.73
Open:
$62.04
24h Volume:
401.63K
Relative Volume:
2.20
Market Cap:
$408.07M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-26.55
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-6.15%
1M Performance:
-24.03%
6M Performance:
+68.46%
1Y Performance:
+158.75%
1-Day Range:
$56.15
$62.13
1-Week Range:
$56.15
$70.01
52-Week Range:
$23.00
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
61.06 | 412.52M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Trading the Move, Not the Narrative: (MNPR) Edition - Stock Traders Daily
EPS Watch: What dividend safety score for Monopar Therapeutics Inc. stock2025 Momentum Check & Verified Swing Trading Watchlists - moha.gov.vn
Monopar Therapeutics announces pricing of $135M offering - MSN
Aug Gainers: Why Monopar Therapeutics Inc stock appeals to analystsProfit Target & Fast Momentum Stock Entry Tips - moha.gov.vn
Hedge Fund Moves: Is Monopar Therapeutics Inc stock a buy for dividend growthSwing Trade & Technical Entry and Exit Alerts - moha.gov.vn
Top Executive Makes Bold Insider Move at Monopar Therapeutics - TipRanks
Insider Buying: Quan Vu Acquires Shares of Monopar Therapeutics Inc (MNPR) - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) CFO Purchases 1,500 Shares - MarketBeat
Monopar therapeutics CFO Vu Quan Anh buys $104925 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (NASDAQ:MNPR) Sharpens Focus on Molecular Targeting - Kalkine Media
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update - MarketBeat
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Zacks Investment Research
Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics - simplywall.st
What dividend safety score for Monopar Therapeutics Inc. stockStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Major Insider Move Shakes Up Investor Watch on Monopar Therapeutics - TipRanks
Is Monopar Therapeutics Inc. stock a safe haven assetJuly 2025 Summary & Accurate Intraday Trading Signals - Улправда
Insider Sell: Arthur Klausner Sells Shares of Monopar Therapeuti - GuruFocus
Dir Klausner Files To Sell 5,121 Of Monopar Therapeutics Inc [MNPR] - TradingView — Track All Markets
Monopar Therapeutics Director Sells Over 5,000 Shares - TradingView — Track All Markets
Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing - marketscreener.com
Dir Klausner Sells 5,121 ($343.9K) Of Monopar Therapeutics Inc [MNPR] - TradingView — Track All Markets
Monopar Therapeutics (FRA:1IY0) EV-to-OCF : -25.58 (As of Dec. 19, 2025) - GuruFocus
Will Monopar Therapeutics Inc. stock gain from strong economyWeekly Stock Report & Weekly High Conviction Ideas - DonanımHaber
Why retail investors favor Monopar Therapeutics Inc. stock2025 Momentum Check & Community Shared Stock Ideas - DonanımHaber
Why Monopar Therapeutics Inc. stock appeals to analystsJuly 2025 PreEarnings & High Return Stock Watch Alerts - DonanımHaber
Is Monopar Therapeutics Inc. (1IY0) stock a good hedge against inflation2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsGold Moves & High Accuracy Swing Trade Signals - Улправда
Treasury Yields: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsInsider Buying & Community Verified Trade Signals - Улправда
Monopar Therapeutics (MNPR) director details 43,499-share distribution in Form 4 - Stock Titan
Monopar Therapeutics (MNPR) director receives 7,710 common shares via distribution - Stock Titan
(MNPR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
Aug Catalysts: How interest rate cuts could boost Monopar Therapeutics Inc stockGap Up & High Accuracy Trade Alerts - moha.gov.vn
Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.3%Should You Buy? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Will Monopar Therapeutics Inc. stock benefit from commodity prices2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
Will Monopar Therapeutics Inc. (1IY0) stock rise with strong economyShare Buyback & Free Weekly Watchlist of Top Performers - Newser
How Monopar Therapeutics Inc. (1IY0) stock behaves in tightening cyclesJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Is Monopar Therapeutics Inc. (1IY0) stock a safe buy pre earningsJuly 2025 Gainers & Verified Technical Signals - Newser
How (MNPR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
How Monopar Therapeutics Inc. (1IY0) stock correlates with oil markets2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Can Monopar Therapeutics Inc. (1IY0) stock stage a strong rebound this quarterRecession Risk & Risk Controlled Stock Alerts - Newser
Is Monopar Therapeutics Inc. (1IY0) stock worth buying before Fed actionMarket Activity Report & High Accuracy Investment Signals - Newser
Is Monopar Therapeutics Inc. stock a safe investment in uncertain markets2025 Support & Resistance & Entry Point Strategy Guides - moha.gov.vn
Monopar Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Free Rapid Portfolio Appreciation - earlytimes.in
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):